Safety of thiopurines and Anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 108, Issue 3, 2013, Pages 433-440

  Casanova, M J ^a   Chaparro, M ^a,b   Domenech E ^b,c   Barreiro De Acosta, M ^d   Bermejo, F ^e   Iglesias, E ^f   Gomollon F ^b,g   Rodrigo, L ^h   Calvet, X ^b,i   Esteve, M ^b,j   Garcia Planella E ^k   Garcia Lopez S ^l   Taxonera, C ^m   Calvo, M ⁿ   Lopez M ^o   Ginard, D ^p   Gomez Garcia M ^q   Garrido, E ^r   Perez Calle J L ^s   Beltran B ^b,t   Piqueras, M ^u   Saro, C ^v   Botella, B ^w   Duenas C ^x   Ponferrada, A ^y   Manosa M ^b,c   Garcia Sanchez V ^f   Mate J ^a,b   Gisbert, J P ^a,b   more..

^a Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g Hospital Clinieo Universitario Lozano Blesa   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HOSPITAL MÚTUA DE TERRASSA   (Spain)

^k HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^l HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^m HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁿ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^o HOSPITAL DE GALDAKAO   (Spain)

^p HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^r HOSPITAL RAMÓN Y CAJAL   (Spain)

^s HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^t HOSPITAL UNIVERSITARIO LA FE   (Spain)

^u Consorcio Sanitario Terrassa ^*  (Spain)

^v Hospital de Cabuees   (Spain)

^w HOSPITAL INFANTA CRISTINA   (Spain)

^x Hospital Universitario San Pedro Alcántara   (Spain)

^y HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; BIRTH WEIGHT; CHORIOAMNIONITIS; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; CROHN DISEASE; DEATH; DISEASE ACTIVITY; DRUG FATALITY; DRUG SAFETY; FEMALE; FETUS WASTAGE; GESTATIONAL AGE; HUMAN; HYDRAMNIOS; INFECTION; KIDNEY ATROPHY; KIDNEY DISEASE; LOW BIRTH WEIGHT; MACROSOMIA; MAJOR CLINICAL STUDY; MATERNAL AGE; PLACENTA PREVIA; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRETERM LABOR MENACE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SELECTIVE ABORTION; SIDE EFFECT; SPONTANEOUS ABORTION; THROMBOCYTHEMIA; TRISOMY 21; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; FEMALE; HUMANS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875214914     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.430     Document Type: Article

References (53)

1. Elbaz G, Fich A, Levy A et al. Inflammatory bowel disease and preterm delivery. Int J Gynaecol Obstet 2005; 90: 193-7.
2. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 255-81, vii.
3. Ferguson CB, Mahsud-Dornan S, Patterson RN. Inflammatory bowel disease in pregnancy. BMJ 2008; 337-a427.
4. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 1984; 25: 52-6.
5. Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med 1986; 79: 221-5.
6. Katz JA, Pore G. Inflammatory bowel disease and pregnancy. Inflamm Bowel Dis 2001; 7: 146-57.
7. Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis 2008; 14: 1736-50.
8. Dominitz JA, Young JCC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a Population-Based Cohort Study. Am J Gastroenterol 2002; 97: 641-8.
9. Mahadevan U, Sandborn WJ, Li DK et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133: 1106-12.
10. Kwan LY, Mahadevan U. Inflammatory bowel disease and pregnancy: an update. Expert Rev Clin Immunol 2010; 6: 643-57.
11. Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut 1980; 21: 469-74.
12. Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease-a population-based cohort study. Am J Obstet Gynecol 1997; 177: 942-6.
13. Fonager K, Soørensen HT, Olsen J et al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998; 93: 2426-30.
14. Moser MA, Okun NB, Mayes DC et al. Crohn's disease, pregnancy, and birth weight. Am J Gastroenterol 2000; 95: 1021-6.
15. van der Woude CJ, Kolacek S, Dotan I et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010; 4: 493-510.
16. Noørgård B, Fonager K, Soørensen HT et al. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol 2000; 95: 3165-70.
17. Dignass A, Van Assche G, Lindsay JO et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010; 4: 28-62.
18. Travis SP, Stange EF, Lémann M et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008; 2: 24-62.
19. Food and Drug Administration. Regulations 1980; 44: 37434-67
20. Noørgård B, Pedersen L, Christensen LA et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-1.
21. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010; 16: 881-95.
22. Coelho J, Beaugerie L, Colombel JF et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60: 198-203.
23. Johnson DL, Jones KL, Chambers CD et al. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology 2009; 136: A-27.
24. Ventura SJ, Mosher WD, Curtin SC et al. Trends in pregnancy rates for the United States, 1976-97: an update. Natl Vital Stat Rep 2001; 49: 1-9.
25. March of Dimes Birth Defects Foundation. Fact Sheets: Birth Defects, Miscarriage, and Stillbirth; Leading Categories of Birth Defects; and Perinatal Profiles: Statistics for Monitoring State Maternal and Infant Health. 2001. http://www.modimes-org.
26. Alstead EM, Ritchie JK, Lennard-Jones JE. et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99: 443-6.
27. Tennenbaum R, Marteau P, Elefant E et al. Pregnancy outcome in inflammatory bowel diseases. Gastroenterol Clin Biol 1999; 23: 464-9.
28. Francella A, Dyan A, Bodian C et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17.
29. Moskovitz DN, Bodian C, Chapman ML et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 656-61.
30. Noørgård B, Pedersen L, Fonager K et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003; 17: 827-34.
31. Langagergaard V, Pedersen L, Gislum M et al. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther 2007; 25: 73-81.
32. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85: 647-54.
33. González-González NL, Medina V, Jiménez A et al. Base de datos perinatales nacionales 2004. Prog Obstet Ginecol 2006; 49: 645-55.
34. Goldstein LH, Dolinsky G, Greenberg R et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696-701.
35. OECD (2012) Health at a Glance: Europe 2012, OECD-Publishing
36. Bermejo E, Cuevas L, Grupo Perif érico del ECEMC et al. Vigilancia epidemiol ó gica de anomal í as cong é nitas en Espa ñ a: an á lisis de los datos del registro del ECEMC en el periodo 1980-2008. Rev Dismor Epidemiol 2009; V: 64-91.
37. Gisbert JP, Chaparro M, Gomollón F. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol 2011; 17: 3467-78.
38. Hawthorne AB, Logan RF, Hawkey CJ et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-2.
39. Cassinotti A, Actis GC, Duca P et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009; 104: 2760-7.
40. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor- > antagonists. Pharmacotherapy 2005; 25: 1181-92.
41. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
42. Katz JA, Antoni C, Keenan GF et al. Outcome of pregnancy in women receiving infl iximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-92.
43. Mahadevan U, Kane S, Sandborn WJ et al. Intentional infl iximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005; 21: 733-8.
44. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
45. Chaparro M, Gisbert JP. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol 2011; 12: 765-73.
46. Vasiliauskas EA, Church JA, Silverman N et al. Case report: evidence for transplacental transfer of maternally administered infl iximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255-8.
47. Friedman S, Regueiro MD. Pregnancy and nursing in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 265-73, xii.
48. Hou JK, Mahadevan U. A 24-year-old pregnant woman with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7: 944-7.
49. Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn's disease on anti-metabolite therapy after infl iximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
50. Domènech E, Hinojosa J, Nos P et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infl iximab: how long should patients be treated? Aliment Pharmacol Ther 2005; 22: 1107-13.
51. Tursi A. Effect of intentional infl iximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease. Dig Liver Dis 2006; 38: 439-40.
52. Zelinkova Z, de Haar C, de Ridder L et al. High intra-uterine exposure to infl iximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053-8.
53. Steenholdt C, Al-Khalaf M, Ainsworth MA et al. Therapeutic infl iximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis 2012; 6: 358-61.